Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
首席执行官
Blaise Coleman
员工
2931
国家
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
上市
0 Comments
分享你的想法
FAQ
Endo International 今天的股价是多少?▼
ENDPQ 当前价格为 $0 USD,过去 24 小时上涨了 +0%。在图表上更密切关注 Endo International 股价表现。
Endo International 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Endo International 的股票以代码 ENDPQ 进行交易。
Endo International 去年的营收是多少?▼
Endo International 去年的营收为 2.01BUSD。
Endo International 去年的净利润是多少?▼
ENDPQ 去年的净收益为 -2.45BUSD。
Endo International 有多少名员工?▼
截至四月 01, 2026,公司共有2,931名员工。
Endo International 属于哪个行业?▼
Endo International从事于Professional, Scientific, and Technical Services行业。